Conditions: Clinically Isolated Syndrome
Allocation:  | Intervention model: PARALLEL
Enrollment: 35
Healthy volunteers: no

Brief summary:
The primary objective of this initiative is to assess the effectiveness of subcutaneous (sc) interferon (IFN) beta - 1a, (Rebif®), versus No Treatment in delaying the conversion to Clinically Definite Multiple Sclerosis (CDMS) - as defined by the occurrence of a second exacerbation - over 96 weeks in subjects that present with Clinically Isolated Syndrome (CIS) accompanied by an abnormal magnetic resonance imaging (MRI). The secondary objectives are to:

* Assess the effectiveness of sc IFN beta - 1a (Rebif®) therapy in reducing the proportion of patients with CIS converting to CDMS
* Assess the safety of sc IFN beta - 1a (Rebif®) in the patients with CIS

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Rebif® intervention 2: No Treatment
Intervention descriptions: intervention 1: 44 microgram (mcg) IFN beta-1a sc once a week (qw) for 96 weeks intervention 2: No treatment for 96 weeks

Protocol document: